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Introduction
Cervical cancer is the most common gynecologic cancer world-
wide [1]. In International Federation of Gynecology and Obstetrics 
(FIGO; revised 2009) stages I–IIA, either surgery or radiotherapy 
(RT) can be administered with similar rates of disease control, sur-
vival, and toxicity. However, the combination of surgery and RT 
increases the complication rates [2–4].
A number of risk factors have been described for recurrence 
after surgery, i.e., parametrial invasion, compromised surgical 
margins, regional lymph node (LN) metastasis, unfavorable histol-
ogy, large tumor, deep (> 50%) stromal invasion (DSI), and lym-
phovascular space involvement (LVSI) [5–8]. In this case, adjuvant 
RT or chemoradiotherapy can be beneficial [2, 9]. However, post-
operative RT fields and treatment volumes are still a matter of de-
bate. The Radiation Therapy Oncology Group (RTOG) recom-
mends delineating the uterine surgical bed, bilateral parametria, 
upper third of the vagina, paravaginal soft tissues, and common, 
external, and internal iliac lymph nodes, and presacral lymphatics 
[10]. However, this field encompasses a large portion of the intesti-
nal segments, and can cause increased toxicity. Therefore, several 
attempts to reduce the RT field have been made. In a pilot study by 
Kridelka et al. [11] ‘small pelvic’ RT produced high local control 
rates with less toxicity. Based on this trial, in 2001, we began treat-
ing all cervical cancer patients with intermediate risk factors using 
small pelvic external beam RT (EBRT) including the surgical bed, 
parametria, upper vagina, and presacral lymphatics. 
In this bi-institutional study, we retrospectively evaluated the 
treatment outcomes and prognostic factors for survival and disease 
control in cervical cancer patients treated with postoperative small 
pelvic EBRT. The toxicity of this treatment field was also 
evaluated.
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Summary
Background: We sought to determine the outcomes of 
adjuvant small pelvic external beam radiotherapy (EBRT) 
and prognostic factors for survival and disease control. 
Patients and Methods: We retrospectively evaluated 113 
cervical cancer patients treated with postoperative me-
dian 50.4-Gy small pelvic EBRT. We treated the surgical 
bed, bilateral parametria, paravaginal soft tissues, upper 
third of the vagina, and presacral lymphatics. Results: 
Median follow-up of all patients and survivors was 58 
and 67 months, respectively. The 2- and 5-year overall 
survival (OS) and disease-free survival rates were 91 and 
82%, and 85 and 74%, respectively. The locoregional fail-
ure rate was 10%. Age was a significant predictor for OS 
and distant metastasis-free survival (DMFS) on univari-
ate analysis. The number of dissected lymph nodes 
being < 30 negatively affected the pelvic recurrence-free 
survival. The only independent predictor on multivariate 
analysis was older age for DMFS. Although no severe 
acute toxicity was observed, late grade ? 3 toxicity de-
veloped in 8 patients. Conclusion: Small pelvic EBRT 
produces satisfactory survival and locoregional control 
with acceptable toxicity, and can be an alternative to 
whole pelvic EBRT in selected cervical cancer patients.
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Patients and Methods
The medical charts of 113 patients with early-stage intermediate-risk cervi-
cal cancer treated between 2001 and 2014 in 2 departments were retrospectively 
evaluated. All patients underwent pretreatment staging involving history, phys-
ical examination, vaginal examination under general anesthesia, hematologic 
and biochemical parameters, chest X-ray, and computed tomography (CT) or 
magnetic resonance imaging (MRI) of the pelvis with/without cystoscopy, rec-
toscopy, and intravenous pyelogram. Patients were eligible if adequate complete 
surgical staging was performed. Adequate LN dissection was described as the 
bilateral dissection of ? 10 obturator and external iliac LNs [12]. Patients with 
?  2 intermediate risk factors (i.e., adenocarcinoma, DSI, LVSI, and >  4  cm 
tumor) or DSI alone were included in the study. All patients were treated with 
small pelvic EBRT. 39 (35%) patients received additional brachytherapy, and 44 
(39%) received concurrent chemotherapy. Patients with distant metastasis or 
high-risk factors (i.e., positive surgical margins, LNs and/or parametria) and 
patients that received chemotherapy prior to RT were excluded from the study. 
This study was approved by the institutional review board. 
All patients received either 2-dimensional (2D) or 3D conformal EBRT in 
supine position with a comfortably full urinary bladder and an empty rectum 
according to RTOG recommendations (RTOG 0418: A Phase II Study of IMRT 
to the Pelvis +/- Chemotherapy for Post-operative Patients with either Endo-
metrial or Cervical Carcinoma; 2011). EBRT was administered via Philips SL25 
(Philips Healthcare, Andover, MA, USA), Elekta Synergy Platform (Elekta AB, 
Stockholm, Sweden), or Varian Clinac DHX High Performance (Varian Medi-
cal Systems, Inc. Palo Alto, CA). In 2D EBRT, the superior border of the RT 
field was the lumbar (L)5-sacral (S)1 vertebral interspace, the inferior border 
was inferior to the obturator foramina, and the lateral borders were adjacent to 
the medial border of iliac bones. For lateral fields, the anterior border was pos-
terior to the symphysis pubis, and the posterior border was the S3–4 vertebral 
interspace. In 3D EBRT, the surgical bed and presacral lymphatics were deline-
ated according to the RTOG guidelines [10]. Common, internal, and external 
iliac LNs as well as obturator LNs were excluded. Organs at risk were detected 
in related slices, and were also contoured (fig. 1). In both 2D and 3D EBRT, a 
pelvic box technique with 4 fields (i.e., antero-posterior, postero-anterior and 2 
laterals) was applied.
Brachytherapy was performed when positive or close (<  5 mm) surgical 
margins on the vagina were reported. A 2D and 3D remote after-loading tech-
nique of high-dose-rate (HDR) brachytherapy was administered via microSe-
lectron® (Elekta AB), GammaMed Plus® (Varian Medical Systems Inc.), or 
VariSource® (Varian Medical Systems Inc.). All patients were treated in supine 
position with an empty urinary bladder and rectum. A vaginal cylinder cover-
ing the whole vagina was placed. The dose was prescribed at a 5-mm distance 
from the mucosa. In 3D brachytherapy, a planning CT with a slice thickness of 
2.5 mm was taken, and the clinical target volume (CTV) was contoured encom-
passing the upper third (length) and whole thickness of the vagina. 
A radiation oncologist followed all patients during the course of RT and, in 
association with a gynecologic oncologist, monitored patients every 3 months 
for the first 2 years, every 6 months until year 5, and annually thereafter. Fol-
low-up information was obtained from department charts, referring doctors, 
and patients and/or next of kin. RTOG/European Organization for the Treat-
ment of Cancer (EORTC) toxicity criteria were used to score RT-related acute 
and late toxicities [13]. 
All statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS) version 18.0 (SPSS Inc., IBM Corp., Armonk, NY, USA). 
The primary end point was pelvic recurrence-free survival (PRFS). Secondary 
end points included overall survival (OS), disease-free survival (DFS), distant 
metastasis-free survival (DMFS), and treatment toxicity. Time to progression was 
calculated as the period from the date of diagnosis to the date of death or disease 
recurrence. Survival analyses were carried out using the Kaplan-Meier method 
and compared using the log-rank test. Multivariate analysis was performed using 
the Cox proportional hazards model, including all factors found significant by 
univariate analysis. p < 0.05 was considered statistically significant.
Results
Patient and treatment characteristics are presented in table  1. 
The median age was 54 years (range 34–84 years). Tumors were 
mostly squamous cell carcinoma. The median number of dissected 
total, pelvic, and para-aortic LNs was 41 (range 12–120), 30 (range 
12–97), and 8 (range 0–36), respectively. 61 (54%) patients received 
2D EBRT, whereas 52 (46%) received 3D EBRT. The median EBRT 
dose was 50.4 Gy (range 45–50.4 Gy) in median 1.8-Gy (range 1.8–2 
Gy) daily fractions. 39 (35%) patients underwent HDR brachyther-
apy with a median 15 Gy (range 12–28 Gy) in 5-Gy (range 4–7 Gy) 
daily fractions. 44 (39%) patients received concurrent 40 mg/m2 
weekly cisplatin with a median of 5 (range 3–6) cycles.
The median follow-up times for all patients and for those that 
survived were 58 months (range 2–177 months) and 67 months 
(range 4–177 months), respectively. In total, 6 patients harbored 
disease (local, locoregional, or distant), including 2 with distant 
Fig. 1. Dose-color wash images of 3-dimentional 
radiotherapy plan in a cervical cancer patient with 
postoperative intermediate risk factors. Right 
upper image: right and left femur depicted in blue 
and pink, respectively. Dose-color wash images are 
seen in transverse, coronal, and sagittal slices in the 
upper left, lower left, and lower right boxes, respec-
tively.
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metastasis, 2 with pelvic recurrence, and 2 with both. At the final 
follow-up, 91 (81%) patients were alive (9 with disease), and 22 
(19%) patients had died (6 of their disease, 17 of other causes). 
The 2- and 5-year OS rate was 91 and 82%, respectively. In uni-
variate analysis, age was the only significant factor (table 2). In mul-
tivariate analysis, no statistically significant factor was observed. 
The 2- and 5-year DFS rate was 85 and 74%, respectively. In uni-
variate analysis, a trend for DFS was observed in patients ? 50 years 
(p = 0.09) and in patients with ? 30 LNs dissected (p = 0.06). No 
statistically significant factor was found in multivariate analysis. 
The 2- and 5-year PRFS rate was 86 and 75%, respectively. The lo-
coregional control rate was 92% in 2 years and 89% in 5 years. The 
2- and 5-year PRFS rates were 74 and 66%, and 92 and 79% in pa-
tients with <  30 and ?  30 dissected LNs, respectively (p = 0.04). 
Multivariate analysis was not performed as there was only 1 statisti-
cally significant factor in univariate analysis. The 2- and 5-year 
DMFS rate was 88 and 79%, respectively. The distant metastasis rate 
was 6% for the entire cohort. The only statistically significant factor 
in univariate analysis was age. The 2- and 5-year DMFS rate was 90 
and 88% in patients ? 50 years compared to 87 and 73% in patients 
> 50 years, respectively (p = 0.02). Although not statistically signifi-
cant, positive/close surgical margins on the vagina resulted in a de-
creased DMFS rate (2- and 5-year DMFS rate 79 and 67% vs. 92 and 
83% in patients with negative margins; p = 0.075). Older age (> 50 
years) was the only significant factor in multivariate analysis (haz-
ard ratio = 2.77, 95% confidence interval 1.02–7.56; p = 0.04).
None of the patients had toxicities that necessitated the discon-
tinuation of RT. No grade ?  3 adverse events occurred during 
EBRT or brachytherapy. 45 (40%) patients developed grade 1–2 
acute toxicity (cystitis, n = 24; proctitis, n = 24; diarrhea, n = 21; 
dermatitis, n = 7). Late serious complications were observed in 8 
(7%) patients: 1 patient each with proctitis, enteritis, lymphedema, 
rectovaginal fistula, rectovesical fistula, enterovesical fistula, femo-
ral aseptic necrosis, and femoral aseptic necrosis with a possibly 
RT-related sarcoma of the iliac bone. The rate of late toxicity in 
patients treated with 2D EBRT was significantly higher compared 
to that in patients treated with 3D EBRT (p = 0.04). However, only 
1 patient with a rectovaginal fistula was treated with 3D EBRT. The 
patient with late proctitis had received 4×7 Gy brachytherapy, and 
also developed grade 2 proctitis during EBRT. Other patients with 
late toxicity had not received brachytherapy, and none of them de-
veloped acute toxicity.
Discussion
The results of the present study revealed that omitting the iliac 
and obturator lymphatics during EBRT in early-stage cervical can-
cer patients with intermediate risk factors does not negatively im-
pact survival and disease control. Additionally, we did not find any 
significant prognosticators for survival or local control, except for 
Table 1. Patient and treatment characteristics
Characteristic Patients, n (%)
Age, years
? 50  41 (36)
> 50  72 (64)
Type of surgery
Type II   4 (3)
Type III 109 (97)
Stage
IA2   1 (1)
IB1  53 (47)
IB2  41 (36)
IB (tumor size not achieved)   2 (2)
IIA1  13 (11)
IIA2   3 (3)
Tumor size, cm
? 2   9 (8)
2–4  58 (51)
> 4  40 (36)
N/A   6 (5)
Histopathology
SCC  98 (87)
Adenocarcinoma  13 (11)
Adenosquamous carcinoma   2 (2)
Cervical stromal invasion, %
? 50   8 (7)
> 50  83 (74)
N/A  22 (19)
Endometrial invasion  24 (21)
Myometrial invasion  12 (11)
Lymphovascular space involvement  56 (49)
Vaginal SM
Positive   4 (4)
Close (< 0.5 cm)  28 (25)
VAIN on SM   2 (2)
In-situ cervical carcinoma on SM   1 (1)
Risk factors, n
1 (only DSI)  19 (17)
2  46 (41)
3  23 (20)
N/A  25 (22)
N/A = Not available; SCC = squamous cell carcinoma; SM = surgical margin; 
VAIN = vaginal intraepithelial neoplasia; DSI = deep stromal invasion.
Table 2. Prognostic factors in univariate analysis for overall survival 
2-year OS, % 5-year OS, % p value
Age, years 0.04a
? 50 90 90
> 50 92 78
Dissected LNs, n 0.08
< 30 75 75
? 30 92 83
SM status 0.09
Positive/close 82 70
Negative 92 86
aStatistically significant.
LN=lymph node; SM=surgical margin.
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age for OS and DMFS. Older patients in our study received a quite 
similar treatment schedule with high compliance rates. We can 
only assume that the reason for the worse outcome in patients > 50 
years may be somewhat aggressive tumor factors other than the al-
ready known.
Postoperative adjuvant RT improves local control in selected 
cases. In the studies on postoperative RT, cervical cancer patients 
mostly have high and intermediate risk factors [14, 15]. In a phase 
III study of patients with intermediate risk factors alone, Sedlis et 
al. [2] treated 277 patients with 46–50.4 Gy EBRT that encom-
passed the obturator and iliac LNs. With a median 10-year follow-
up, the authors reported DFS rates of 82.5% in patients treated 
with adjuvant RT and 69.3% for no further treatment [16]. The lo-
coregional recurrence rate was 13.9 and 20.7% in the respective pa-
tients. The overall pelvic disease control rate in our study was 
90.3% which is quite similar to the above study with whole pelvic 
EBRT.
A number of studies did not recommend adjuvant RT in early-
stage cervical cancer with intermediate risk factors as it did not in-
crease disease control and survival rates [17, 18]. Nevertheless, the 
majority of studies has come up with opposite results. DSI and 
tumor size were demonstrated as strong prognostic factors for OS, 
DFS, and DMFS [9, 19, 20]. In the Gynecologic Oncology Group 
(GOG)-49 study, Delgado et al. [21] demonstrated that tumor size, 
LVSI, and DSI were independent predictors for DFS in stage IB 
disease. In the GOG-92 study with 277 patients having ? 2 inter-
mediate risk factors, compared to surgery alone, adjuvant RT in-
cluding iliac and obturator LNs reduced the recurrence and mor-
tality risk by 44 and 36%, respectively [2]. In the update of this 
study with a median 10-year follow-up, local and distant failures 
were still higher in the surgery-only arm compared to the adjuvant 
RT arm (20.7 vs. 13.9%, and 8.6 vs. 2.9%) with similar OS rates (70 
vs. 81%) [16]. Based on these findings, we began delivering adju-
vant RT to all patients with DSI alone or ? 2 intermediate risk fac-
tors. However, we found none of the intermediate risk factors to be 
a significant prognostic factor in the current study. The routine use 
of adjuvant RT may have precluded these risk factors and hence 
the determination of their effect on local and distant recurrence. 
According to the American College of Radiology (ACR) Appro-
priateness Criteria, patients with early-stage cervical cancer are di-
vided into 3 risk groups following radical surgery, and patients 
with LVSI, DSI, and/or large tumor constitute the intermediate-
risk group [22]. Adjuvant RT is indicated in this group as the re-
currence risk is approximately 30%. For adjuvant RT, ACR recom-
mends that the CTV should encompass the paracervical, parame-
trial, and paravaginal soft tissues, the upper vagina, the ligaments 
supporting the cervix, and all LNs at high risk of involvement [22]. 
In 2D simulation, the superior border is the L5-S1 vertebral inter-
space, the inferior border is inferior to the iliac bones, and the lat-
eral borders are 2 cm lateral to the iliac foramina. In our small pel-
vic field, the superior border is the L5-S1 vertebral interspace, but 
the inferior border is just inferior to the iliac foramina and the lat-
eral borders are lateral to these. Hence, our field is relatively 
smaller than conventional fields. Nevertheless, only 10% of patients 
experienced pelvic recurrence in a median follow-up of 58 months. 
Our results are comparable with those of Kriedelka et al. [11] who 
used small pelvic fields in 25 patients with intermediate risk factors 
of whom only 1 patient recurred. 
RTOG published a consensus guideline for IMRT in postopera-
tive endometrial and cervical cancer [10]. They recommend delin-
eating common, external, and internal iliac LNs as well as presacral 
LNs together with the uterine and cervical surgical bed, bilateral 
parametria, upper third of the vagina, and paravaginal soft tissues. 
We strictly follow this guideline when determining targets. How-
ever, we irradiate presacral lymphatics alone in patients with ade-
quate LN dissection. We give an at least 1.5-cm margin for the 
planning target volume based on organ motion according to our 
previous study with sequential CT scans at different time periods 
of treatment [23]. 
None of our patients experienced toxicity that necessitated the 
discontinuation of RT. Only 8 patients developed considerable late 
toxicity. In studies on cervical cancer patients with high and inter-
mediate risk factors treated with adjuvant low pelvic field EBRT 
(i.e., exclusion of common iliac LNs), local and distant control 
rates were found to be similar to those in patients treated with 
whole pelvic RT with much lower rates of gastrointestinal compli-
cations [15, 24, 25]. In our study, delineating only the presacral 
LNs resulted in an excellent pelvic control rate of 90.3% compared 
to studies with whole pelvic EBRT [14, 26]. A 5-year OS rate of 
82% and the absence of grade ?  3 acute toxicity also reveal that 
adjuvant small pelvic EBRT is an adequate and sufficient treatment 
for patients with intermediate risk factors.
The main limitations of our study are that it is retrospective in 
nature, and it only presents the results of small pelvic EBRT with-
out comparing it to whole pelvic EBRT. However, this study is im-
portant in that it offers a somewhat innovative technique to radia-
tion oncologists which leads to excellent disease control with negli-
gible toxicity. Although there are previously published studies pre-
senting acceptable outcomes with small pelvic EBRT, our study is 
the only one that applied a true small pelvic field. Besides the iden-
tified intermediate risk factors, older age and < 30 LN dissection 
deteriorated the prognosis. On the other hand, prospective trials 
analyzing the treatment outcomes and prognostic factors for small 
and whole pelvic field irradiation are required for accurate decision 
making. 
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